• 1
    Firestein GS, Xu WD, Townsend K, Broide D, AlvaroGracia J, Glasebrook A, Zvaifler NJ: Cytokines in chronic inflammatory arthritis. I. Failure to detect T cell lymphokines (interleukin 2 and interleukin 3) and presence of macrophage colony-stimulating factor (CSF-1) and a novel mast cell growth factor in rheumatoid synovitis. J Exp Med 168: 15731586, 1988
  • 2
    Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K: Augmented interleukin-1 production and HLA–DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis Rheum 31: 480486, 1988
  • 3
    Firestein GS, Alvaro-Gracia JM, Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144: 33473353, 1990
  • 4
    Hamerman D, Wood DD: Interleukin-1 enhances synovial cell hyaluronate synthesis. Proc Soc Exp Biol Med 177: 205210, 1984
  • 5
    Butler DM, Vitti GF, Leizer T, Hamilton JA: Stimulation of the hyaluronic acid levels of human synovial fibroblasts by recombinant human tumor necrosis factor α, tumor necrosis factor b̃ (lymphotoxin), interleukin-1α, and interleukin-1b̃. Arthritis Rheum 31: 12811289, 1988
  • 6
    Engström-Laurent A, Hallgren R: Circulating hyaluronate in rheumatoid arthritis: relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 44: 8388, 1985
  • 7
    Engström-Laurent A, Hallgren R: Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients: relationship to synovitis mass and morning stiffness. Arthritis Rheum 30: 13331338, 1987
  • 8
    Poole AR, Witter J, Roberts N, Piccolo F, Brandt R, Paquin J, Baron M: Inflammation and cartilage metabolism in rheumatoid arthritis: studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. Arthritis Rheum 33: 790799, 1990
  • 9
    Goldberg RL, Huff JP, Lenz ME, Glickman P, Katz R, Thonar EJ-MA: Elevated plasma levels of hyaluronate in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 34: 799807, 1991
  • 10
    Hascall VC: Proteoglycans: the chondroitin sulfate/keratan sulfate proteoglycan of cartilage. ISI Atlas Sci Biochem 1: 189198, 1988
  • 11
    Hardingham T: Proteoglycans: their structure, interactions and molecular organization in cartilage. Biochem Soc Trans 9: 489497, 1981
  • 12
    Maroudas A: Physical chemistry of articular cartilage and the intervertebral disc, The Joints and Synovial Fluid. Vol. 2. Edited by LSokoloff. New York, Academic Press, 1980
  • 13
    Hardingham T, Muir H, Kwan MK, Lai WM, Mow VC: Viscoelastic properties of proteoglycan solutions with varying proportions present as aggregates. J Orthop Res 5: 3646, 1987
  • 14
    Woessner JF Jr, Selzer MG: Two latent metalloproteinases of human articular cartilage that digest proteoglycan. J Biol Chem 259: 36333638, 1984
  • 15
    Thonar EJ-MA, Lenz ME, Klintworth GK, Caterson B, Pachman LM, Glickman P, Katz R, Huff J, Kuettner KE: Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum 28: 13671376, 1985
  • 16
    Saxne T, Heinegard D, Wollheim FA: Therapeutic effects on cartilage metabolism in arthritis as measured by the release of proteoglycan structures into the synovial fluid. Ann Rheum Dis 45: 491497, 1986
  • 17
    Witter J, Roughley PJ, Webber C, Roberts N, Keystone E, Poole AR: The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum 30: 519529, 1987
  • 18
    Ratcliffe A, Doherty M, Maine RN, Hardingham TE: Increased concentrations of proteoglycan components in the synovial fluid of patients with acute but not chronic joint disease. Ann Rheum Dis 47: 826832, 1988
  • 19
    Lohmander LS, Dahlberg L, Ryd L, Heinegård D: Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 32: 14341442, 1989
  • 20
    Sweet MBE, Coelho A, Schnitzler CM, Schnitzer TJ, Lenz ME, Jakim I, Kuettner KE, Thonar EJ-MA: Serum keratan sulfate levels in osteoarthritis patients. Arthritis Rheum 31: 648652, 1988
  • 21
    Williams JM, Downey C, Thonar EJ-MA: Increase in levels of serum keratan sulfate following cartilage proteoglycan degradation in the rabbit knee joint. Arthritis Rheum 31: 557560, 1988
  • 22
    Leipold HR, Goldberg RL, Lust G: Canine serum keratan sulfate and hyaluronate concentrations. Arthritis Rheum 32: 312321, 1989
  • 23
    Mehraban F, Moskowitz RW: Serum keratan sulfate levels in rabbits with experimentally induced osteoarthritis. Arthritis Rheum 32: 12931299, 1989
  • 24
    Block JA, Schnitzer TJ, Andersson GBJ, Lenz ME, Jeffery R, McNeill TW, Thonar EJ-MA: The effect of chemonucleolysis on serum keratan sulfate levels in humans. Arthritis Rheum 32: 100105, 1989
  • 25
    Mehraban F, Finegan CK, Moskowitz RW: Serum keratan sulfate: quantitative and qualitative comparisons in inflammatory versus noninflammatory arthritides. Arthritis Rheum 34: 383392, 1991
  • 26
    Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA: Revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 2: 1620, 1959
  • 27
    Lansbury J: Report of a three-year study on the systemic and articular indexes in rheumatoid arthritis: theoretic and clinical considerations. Arthritis Rheum 1: 505522, 1958
  • 28
    Li XQ, Thonar EJ-MA, Knudson W: Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA. Connect Tissue Res 19: 243253, 1989
  • 29
    Lindquist U, Chichibu K, Delpech B, Goldberg RL, Knudson W, Poole AR, Laurent TC: A comparative study of seven different assays for hyaluronan. Clin Chem (in press)
  • 30
    Saxne T, Hayford J, Heinegard D, Lenz ME, Thonar E, Wollheim FA, Pachman L: Serum levels of the proteoglycan core protein and keratan sulfate correlate in juvenile rheumatoid arthritis (abstract). Arthritis Rheum 32 (suppl 4): S105, 1989
  • 31
    Laurent TC, Dahl IMS, Dahl LB, Engström-Laurent A, Eriksson S, Fraser JR, Granath KA, Laurent C, Laurent UB, Lilja K: The catabolic fate of hyaluronic acid. Connect Tissue Res 15: 3341, 1986
  • 32
    Ludolph T, Paschke E, Glossl J, Kresse H: Degradation of keratan sulfate by b̃-N-acetylhexosaminidases A and B. Biochem J 193: 811818, 1981
  • 33
    Barka N, Tomasi JP, Stadsbaeder S: Use of whole Streptococcus Pneumoniae cells as a solid phase sorbent for C-reactive protein measurement by ELISA. J Immunol Methods 82: 5763, 1985
  • 34
    Saxne T, Palladino MA Jr, Heinegård D, Talal N, Wollheim FA: Detection of tumor necrosis factor α but not tumor necrosis factor b̃ in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31: 10411045, 1988
  • 35
    Houssiau FA, Devogelaer J-P, van Damme J, Nagant de Deuxchaisnes C, van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31: 784788, 1988
  • 36
    Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage–pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34: 11251132, 1991
  • 37
    Arend WP, Dayer J-M: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 33: 305315, 1990
  • 38
    Van Snick J: Interleukin-6: an overview. Annu Rev Immunol 8: 253278, 1990
  • 39
    Guerne PA, Carson DA, Lotz M: IL-6 production by human articular chondrocytes: modulation of its synthesis by cytokines, growth factors and hormones in vitro. J Immunol 144: 499505, 1990
  • 40
    Bunning RAD, Russell RGG, van Damme J: Independent induction of interleukin 6 and prostaglandin E2 by interleukin 1 in human articular chondrocytes. Biochem Biophys Res Commun 166: 11631170, 1990
  • 41
    Kandel RA, Petellycky M, Dinarello CA, Minden M, Pritzker KPH, Cruz TF: Comparison of the effect of interleukin 6 and interleukin 1 on collagenase and proteoglycan production by chondrocytes. J Rheumatol 17: 953957, 1990
  • 42
    Darlington GJ, Wilson DR, Lachman LB: Monocyte-conditioned medium, interleukin 1 and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 103: 787793, 1986
  • 43
    Perlmutter DH, Dinarello CA, Punsal PI, Colten HR: Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 78: 13491354, 1986
  • 44
    Antonas KN, Fraser JRE, Muirden KD: Distribution of biologically labelled radioactive hyaluronic acid injected into joints. Ann Rheum Dis 32: 103111, 1973
  • 45
    Fraser JRE, Engström-Laurent A, Nyberg A, Laurent TC: Removal of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med 107: 7985, 1986
  • 46
    Konttinen YT, Saari H, Honkanen VEA, Szocsik K, Mussalo-Rauhamaa H, Tulensalo R, Friman C: Serum baseline hyaluronate and disease activity in rheumatoid arthritis. Clin Chim Acta 193: 3948, 1990
  • 47
    Paimela L, Heiskanen A, Kurki P, Helve T, Leirisalo-Repo M: Serum hyaluronate level as a predictor of radiologic progression in early rheumatoid arthritis. Arthritis Rheum 34: 815821, 1991
  • 48
    Björk J, Kleinau S, Tengblad A, Smedegård G: Elevated levels of serum hyaluronate and correlation with disease activity in experimental models of arthritis. Arthritis Rheum 32: 306311, 1989
  • 49
    Forrester JV, Balazs EA: Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 40: 435446, 1980
  • 50
    Fraser JRE, Claris BJ: On the reactions of human synovial cells exposed to homologous leucocytes in vitro. Clin Exp Immunol 6: 211223, 1970
  • 51
    Levesque H, Delpech B, le Loet X, Deshayes P: Serum hyaluronate in rheumatoid arthritis: study by affino-immunoenzymatic assay. Br J Rheumatol 27: 445449, 1988
  • 52
    Horslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I: Serum aminoterminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months treatment with the levamisole penicillamine or azathropine. Ann Rheum Dis 47: 116126, 1988
  • 53
    Fassbender HG: Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Coll Relat Res 3: 141155, 1983
  • 54
    O'Sullivan FX, Fassbender H-G, Gay S, Koopman WJ: Etiopathogenesis of the rheumatoid arthritis–like disease of MRL/1 mice. I. The histomorphologic basis of joint destruction. Arthritis Rheum 28: 529536, 1985
  • 55
    Thonar EJ-MA, Manicourt DH, Williams J, Fukuka K, Campion GV, Sweet BMA, Lenz ME, Schnitzer TJ, Kuettner K: Serum keratan sulfate: a measure of cartilage proteoglycan metabolism, Articular Cartilage and Osteoarthritis. Edited by KEKuettner, RSchleyerbach, JGPeyron, VCHascall. New York, Raven Press, 1992
  • 56
    Seibel MJ, Towbin H, Braun DG, Kiefer B, Muller W, Paulsson M: Serum keratan sulphate in rheumatoid arthritis and different clinical subsets of osteoarthritis, Keratan Sulphate: Chemistry, Biology, Chemical Pathology. Edited by HGreiling, JEScott. London, Biochemical Society, 1989
  • 57
    Nietfeld JJ, Wilbrink B, Helle M, van Roy JLAM, den Otter W, Swaak AJG, Huber-Brunning O: Interleukin-1–induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 33: 16951701, 1990
  • 58
    Saklatvala J: Tumor necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycans in cartilage. Nature 322: 547549, 1986
  • 59
    Dingle JT: Cartilage maintenance in osteoarthritis: interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair. J Rheumatol 18 (suppl 28): 3037, 1991
  • 60
    Campion GV, Schnitzer TJ, Zeitz H, Lenz ME, Lindeman M, Thonar EJ-MA: The effect of oral administration of prednisolone and of the non-steroidal anti-inflammatory drugs piroxicam and naproxen on serum levels of keratan sulfate (abstract). Orthop Res Soc Trans 15: 334, 1990